Sino Biological US, Inc. has announced the launch of ProPure™, a new line of ultra-pure, endotoxin-free recombinant proteins, produced at its state-of-the-art Center for Bioprocessing (C4B) facility in Houston, Texas. This development marks a significant advancement in the field of bioprocessing, offering researchers and biomanufacturers proteins with endotoxin levels below the limit of quantification (LOQ), crucial for sensitive applications in immunology research, vaccine development, and therapeutic protein manufacturing.
The ProPure™ product line is the result of advanced purification and production technologies, leveraging mammalian expression systems and proprietary purification protocols. This ensures the highest standards of quality and consistency, addressing the critical need for endotoxin-free proteins in research and production environments where even trace contamination can lead to compromised results or patient safety issues.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized the company's commitment to scientific excellence and product safety, stating that the ProPure™ line empowers breakthroughs in both basic and translational science. The launch reflects Sino Biological's investment in bioprocessing innovation and its dedication to supporting the global life sciences community, including offering customized protein development services to meet unique research and production needs.
This announcement is significant for the life sciences industry, as it sets a new benchmark for protein purity and safety, potentially accelerating advancements in vaccine development, cell and gene therapy, and other critical areas of medical research. The availability of high-purity, endotoxin-free proteins like those in the ProPure™ line is essential for ensuring the reliability and reproducibility of scientific studies, ultimately contributing to the development of safer and more effective therapeutics.
